Sanofi Pasteur Inc.

The Kingdom of the Netherlands, Represented by the Minister of Health, Welfare and Sport, on Behalf of the Minister, the National Institute of Public Health and the Environment

The Kingdom of the Netherlands, Represented by the Mininster of Health, Welfare and Sport, on Behalf of the Minster the National Institute of Public Health and the Environment

Jeremy Yethon

Eliud Oloo

Raymond Oomen

Martina Ochs-Onolemhemhen

Martina Ochs

Robert Charlebois

Roger Brookes

Jacqueline McCluskey

Laurence Quemeneur

Michael Leach

This disclosure relates to immunogenic compositions comprising mutantpneumolysin (PLY) proteins. Nucleic acids, polypeptides encoded thereby, compositions containing the same, methods for using such nucleic acids, polypeptides and compositions are also provided.

[object Object]

Provided herein are compositions and methods for eliciting an immune response against. The compositions and methods relate topolypeptides and fragments and variants thereof and the corresponding polynucleotides which are useful in the diagnosis, prevention and therapy ofinfections (e.g. periodontitis). Antibodies against the polypeptides and compositions and methods including these antibodies are also disclosed. The disclosure also describes methods for the detection, prevention and treatment ofinfection (e.g. periodontitis).

Porphyromonas gingivalis polypeptides

This disclosure relates to modifiedpneumolysm (PLY) proteins which lack hemolytic activity and can be used as immunogens in an immunogenic composition or vaccine against invasive pneumococcol diseases caused byThe modified pneumolysm proteins comprise amino acid substitutions at threonine 65, glycine 293 and cysteine 428 Nucleic acids, polypeptides encoded thereby, compositions containing the same, methods for using such nucleic acids, polypeptides and compositions are also provided.

This disclosure relates to modifiedpneumolysm (PLY) proteins which lack hemolytic activity and can be used as immunogens in an immunogenic composition or vaccine against invasive pneumococcol diseases caused by. The modified pneumolysm proteins comprise ammo acid substitutions at threonine 65, glycine 293 and cysteine 428 Nucleic acids, polypeptides encoded thereby, compositions containing the same, methods for using such nucleic acids, polypeptides and compositions are also provided.

Provided herein are compositions and methods for eliciting an immune response against. More particularly, the compositions and methods relate to immunogenic polypeptides, including fragments of PhtD and variants thereof, and nucleic acids, vectors and transfected cells that encode or express the polypeptides. Methods of making and using the immunogenic polypeptides are also described.

Growing community of inventors

Boston, MA, United States of America

Jeremy Yethon